Published May 29, 2013 | Version v1
Journal article

Expression of a LINE-1 endonuclease variant in gastric cancer: its association with clinicopathological parameters

  • 1. Department of Geriatric Gastroenterology, China PLA General Hospital, Beijing (China)
  • 2. Department of Geriatric Medicine, China PLA General Hospital, Beijing (China)
  • 3. Department of Pathology, China PLA General Hospital, Beijing (China)
  • 4. Department of Pathology, Cancer Institute (Hospital), Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing (China)

Description

Long interspersed nuclear element-1 (LINE-1 or L1), the most abundant and only autonomously active family of non-LTR retrotransposons in the human genome, expressed not only in the germ lines but also in somatic tissues. It contributes to genetic instability, aging, and age-related diseases, such as cancer. Our previous study identified in human gastric adenocarcinoma an upregulated transcript GCRG213, which shared 88% homology with human L1 sequence and contained a putative conserved apurinic/apyrimidinic endonucleas1 domain. Immunohistochemistry was carried out by using a monoclonal mouse anti-human GCRG213 protein (GCRG213p) antibody produced in our laboratory, on tissue microarray constructed with specimens from 175 gastric adenocarcinoma patients. The correlation between GCRG213p expression and patient clinicopathological parameters was evaluated. GCRG213p expression in gastric cancer cell lines were studied using Western blotting analysis. L1 promoter methylation status of gastric cancer cells was tested using methylation-specific PCR. BLASTP was used at the NCBI Blast server to identify GCRG213p sequence to any alignments in the Protein Data Bank databases. Most primary gastric cancer, lymph node metastases and gastric intestinal metaplasia glands showed positive GCRG213p immunoreactivity. High GCRG213p immunostaining score in the primary gastric cancer was positively correlated with tumor differentiation (well differentiated, p = 0.001), Lauren's classification (intestinal type, p < 0.05) and a late age onset of gastric adenocarcinoma (≥65 yrs; p < 0.05). GCRG213p expression has no association with other clinicopathological parameters, including survival. Western blotting analysis of GCRG213p expression in gastric cancer cells indicated that GCRG213p level was higher in gastric cancer cell lines than in human normal gastric epithelium immortalized cell line GES-1. Partial methylation of L1 in gastric cancer cells was confirmed by methylation-specific PCR. BLASTP program analysis revealed that GCRG213p peptide shared 83.0% alignment with the C-terminal region of L1 endonuclease (L1-EN). GCRG213p sequence possesses the important residues that compose the conserved features of L1-EN. GCRG213p could be a variant of L1-EN, a functional member of L1-EN family. Overexpression of GCRG213p is common in both primary gastric cancer and lymph node metastasis. These findings provide evidence of somatic L1 expression in gastric cancer, and its potential consequences in the form of tumor

Availability note (English)

Available from http://dx.doi.org/10.1186/1471-2407-13-265; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670995

Additional details

Publishing Information

Journal Title
BMC cancer (Online)
Journal Volume
13
Journal Page Range
p. 265
ISSN
1471-2407

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
46123668
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
CARCINOMAS; COMMERCIAL BUILDINGS; EXPLOSIONS; LYMPH NODES; PATIENTS; POLYMERASE CHAIN REACTION
Descriptors DEC
BUILDINGS; DISEASES; GENE AMPLIFICATION; LYMPHATIC SYSTEM; NEOPLASMS

Optional Information

Copyright
Copyright (c) 2013 Wang et al.
Notes
PMCID: PMC3670995; PUBLISHER-ID: 1471-2407-13-265; PMID: 23718141; OAI: oai:pubmedcentral.nih.gov:3670995; licensee BioMed Central Ltd.